Pharmacological profile of a new topical pilocarpine formulation.
A new formulation based on pilocarpine hyaluronate salt has been shown to improve the bioavailability of the drug and to extend the duration of activity. We evaluated the extent of intraocular pressure reduction, the duration of action and the kinetics of miotic response of this formulation in comparison with a commercial preparation with the same drug concentration. Ocular hypertension in the rabbit was induced by alpha-chymotrypsin or by water loading. The hypotensive effect of the new formulation treatment was significantly greater and longer than that observed in rabbit eyes treated with the commercial preparation both in the normotensive and in the hypertensive animals. Furthermore, we evaluated the miotic response in normotensive rabbits showing a greater miotic response and an extended duration when the eyes were treated with the new formulation. The pharmacological profile of the new formulation described in this study indicates an increase of efficacy and duration of action compared to the commercial preparation.
Bucolo
C
C
Fidia Oftal Research Laboratories, Catania, Italy.
Mangiafico
P
P
D000818:Animals; D001682:Biological Availability; D002918:Chymotrypsin; D006820:Hyaluronic Acid; D007700:Kinetics; D015877:Miosis / Q000139:chemically induced; D009798:Ocular Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D010862:Pilocarpine / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D013997:Time Factors; D014867:Water
D010862:Pilocarpine; D014867:Water; D006820:Hyaluronic Acid; D002918:Chymotrypsin; C117608:alpha-chymotrypsin